Loading clinical trials...

Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia | Clinical Trials | Clareo Health

UNKNOWNPHASE2

Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

Phase II Trial of CLAG-M in Relapsed ALL

NCT01513603•New York Medical College

View on ClinicalTrials.gov

Summary

CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.

Detailed Description

Patients will receive standard dose CLAG-M (cladribine, cytarabine, mitoxantrone, filgrastim). Standard support care will be given. Efficacy will be assessed through bone marrow examinations and blood tests.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Relapsed or refractory acute lymphoblastic leukemia,
•Burkitts leukemia/lymphoma,
•Lymphoid blastic CML,
•Lymphoblastic lymphoma.

Locations (1)

Westchester Medical Center/New York Medical College

Valhalla, New York, United States

Key Dates

Start Date

January 1, 2012

Primary Completion Date

January 1, 2014

Completion Date

January 1, 2014

Last Updated

January 20, 2012

Enrollment

ESTIMATED participants

Conditions

Acute Lymphoblastic LeukemiaLymphoblastic LymphomaBurkitts Leukemia/LymphomaChronic Myelogenous Leukemia

Interventions

CLAG-M

DRUG

CLAG-M

DRUG

Contacts

Karen Seiter, MD

CONTACT

914 493 7514 karen_seiter@nymc.edu

Nasir Ahmed, MD

CONTACT

914 493 7514 nasir_ahmed@nymc.edu

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

NCT05376111

T-cell Acute Lymphoblastic LeukemiaRecruiting

View study

RECRUITINGPHASE1/PHASE2

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399

Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 20, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

Inclusion Criteria

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Venetoclax Basket Trial for High Risk Hematologic Malignancies